Literature DB >> 21830099

Signal profile on Gd-EOB-DTPA-enhanced MR imaging in non-alcoholic steatohepatitis and liver cirrhosis induced in rats: correlation with transporter expression.

Natsuko Tsuda1, Osamu Matsui.   

Abstract

OBJECTIVES: To compare the transporter expression and signal profile on Gd-EOB-DTPA-enhanced MRI between non-alcoholic steatohepatitis (NASH) and cirrhotic liver induced in rats, and investigate the correlation of the transporter expression and fibrosis rate in both diseases.
METHODS: Forty-eight rats were divided into four groups of 12: TAA (cirrhosis), NASH 7- and 10-week, and control groups. Each group was divided into two subgroups: Group 1 for MRI and Group 2 for transporter examinations.
RESULTS: The relative enhancement of the TAA group was significantly lower than those of other groups (p < 0.01). The T(max) and T(1/2) of the NASH 10-week group was significantly prolonged in comparison with the TAA group (p < 0.01). There was no significant difference in the oatp1 expression, whereas the mrp2 expression of the TAA group was significantly higher than those of other groups (p < 0.01). There was no significant correlation between the fibrosis rate and oatp1 expression, whereas a paradoxical correlation was found between the fibrosis rate and mrp2 expression (NASH: negative correlation, r = 0.91, p < 0.01; TAA: positive correlation, r = 0.85, p < 0.01).
CONCLUSIONS: Our findings showed that the mrp2 expression in cirrhosis increases in comparison with NASH, and there was a paradoxical correlation between the fibrosis rate and mrp2 expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21830099     DOI: 10.1007/s00330-011-2228-x

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  28 in total

1.  Application of metabonomics on an experimental model of fibrosis and cirrhosis induced by thioacetamide in rats.

Authors:  Maria A Constantinou; Stamatios E Theocharis; Emmanuel Mikros
Journal:  Toxicol Appl Pharmacol       Date:  2006-10-13       Impact factor: 4.219

2.  Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.

Authors:  Marcela Salomao; Woojin M Yu; Robert S Brown; Jean C Emond; Jay H Lefkowitch
Journal:  Am J Surg Pathol       Date:  2010-11       Impact factor: 6.394

3.  Enhancement by estradiol 3-benzoate in thioacetamide-induced liver cirrhosis of rats.

Authors:  Jin Seok Kang; Hideki Wanibuchi; Keiichirou Morimura; Rawiwan Puatanachokchai; Elsayed I Salim; Atsushi Hagihara; Shuichi Seki; Shoji Fukushima
Journal:  Toxicol Sci       Date:  2005-02-16       Impact factor: 4.849

4.  Suppression of ABCA1 by unsaturated fatty acids leads to lipid accumulation in HepG2 cells.

Authors:  Yanhong Yang; Ying Jiang; Yutong Wang; Wei An
Journal:  Biochimie       Date:  2010-04-10       Impact factor: 4.079

5.  Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1.

Authors:  J E van Montfoort; B Stieger; D K Meijer; H J Weinmann; P J Meier; K E Fattinger
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

6.  Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features.

Authors:  Azusa Kitao; Yoh Zen; Osamu Matsui; Toshifumi Gabata; Satoshi Kobayashi; Wataru Koda; Kazuto Kozaka; Norihide Yoneda; Tatsuya Yamashita; Shuichi Kaneko; Yasuni Nakanuma
Journal:  Radiology       Date:  2010-07-27       Impact factor: 11.105

7.  Evaluation of quantitative portal venous, hepatic arterial, and total hepatic tissue blood flow using xenon CT in alcoholic liver cirrhosis-comparison with liver cirrhosis related to hepatitis C virus and nonalcoholic steatohepatitis.

Authors:  Hideaki Takahashi; Michihiro Suzuki; Hiroki Ikeda; Minoru Kobayashi; Shigeru Sase; Hiroshi Yotsuyanagi; Shiro Maeyama; Shiro Iino; Fumio Itoh
Journal:  Alcohol Clin Exp Res       Date:  2009-11-05       Impact factor: 3.455

8.  Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats.

Authors:  Craig D Fisher; Andrew J Lickteig; Lisa M Augustine; Ronald P J Oude Elferink; David G Besselsen; Robert P Erickson; Nathan J Cherrington
Journal:  Eur J Pharmacol       Date:  2009-04-07       Impact factor: 4.432

9.  Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents.

Authors:  L Pascolo; F Cupelli; P L Anelli; V Lorusso; M Visigalli; F Uggeri; C Tiribelli
Journal:  Biochem Biophys Res Commun       Date:  1999-04-21       Impact factor: 3.575

10.  Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease.

Authors:  Andrew J Lickteig; Craig D Fisher; Lisa M Augustine; Lauren M Aleksunes; David G Besselsen; Angela L Slitt; Jose E Manautou; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2007-07-19       Impact factor: 3.922

View more
  10 in total

Review 1.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-09       Impact factor: 11.105

Review 2.  Effect of Liver Disease on Hepatic Transporter Expression and Function.

Authors:  Nilay Thakkar; Jason R Slizgi; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2017-04-30       Impact factor: 3.534

3.  Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease.

Authors:  Ying Ding; Sheng-Xiang Rao; Tao Meng; Caizhong Chen; Renchen Li; Meng-Su Zeng
Journal:  Eur Radiol       Date:  2014-01-26       Impact factor: 5.315

4.  Age dependence of spleen- and muscle-corrected hepatic signal enhancement on hepatobiliary phase gadoxetate MRI.

Authors:  Simon Matoori; Johannes M Froehlich; Stefan Breitenstein; Aleksis Doert; Viktoria Pozdniakova; Dow-Mu Koh; Andreas Gutzeit
Journal:  Eur Radiol       Date:  2015-09-03       Impact factor: 5.315

5.  cDNA Microarray Analysis and Influx Transporter OATP1B1 in Liver Cells After Exposure to Gadoxetate Disodium, a Gadolinium-based Contrast Agent in MRI Liver Imaging.

Authors:  Chi-Cheng Lu; Wen-Kang Chen; Jo-Hua Chiang; Yuh-Feng Tsai; Yu-Ning Juan; Ping-Chin Lin; Yeu-Sheng Tyan; Jai-Sing Yang
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

6.  Development of a novel rat model of heterogeneous hepatic injury by injection with colchicine via the splenic vein.

Authors:  Yan-Yan Zhang; Chao-Xu Zhang; Yu Li; Xuan Jiang; Yong-Fang Wang; Yang Sun; Jun Wang; Wan-Ying Ji; Yi Liu
Journal:  World J Gastroenterol       Date:  2018-11-28       Impact factor: 5.742

7.  Model-inferred mechanisms of liver function from magnetic resonance imaging data: Validation and variation across a clinically relevant cohort.

Authors:  Mikael F Forsgren; Markus Karlsson; Olof Dahlqvist Leinhard; Nils Dahlström; Bengt Norén; Thobias Romu; Simone Ignatova; Mattias Ekstedt; Stergios Kechagias; Peter Lundberg; Gunnar Cedersund
Journal:  PLoS Comput Biol       Date:  2019-06-25       Impact factor: 4.475

8.  Gadoxetic acid-enhanced MRI and sonoelastography: non-invasive assessments of chemoprevention of liver fibrosis in thioacetamide-induced rats with Sho-Saiko-To.

Authors:  Ya-Wen Chen; Meng-Yuan Tsai; Huay-Ben Pan; Hui-Hwa Tseng; Yu-Ting Hung; Chen-Pin Chou
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

9.  Disodium gadoxetate uptake in progressive familial intrahepatic cholestasis type I: Enhancing our understanding of the cholestatic disease.

Authors:  Mikin V Patel; Shlomo Leibowich; Jesse L Courtier; Sue Rhee; John D MacKenzie
Journal:  Radiol Case Rep       Date:  2015-12-07

10.  A multi-center preclinical study of gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function.

Authors:  Anastassia Karageorgis; Stephen C Lenhard; Brittany Yerby; Mikael F Forsgren; Serguei Liachenko; Edvin Johansson; Mark A Pilling; Richard A Peterson; Xi Yang; Dominic P Williams; Sharon E Ungersma; Ryan E Morgan; Kim L R Brouwer; Beat M Jucker; Paul D Hockings
Journal:  PLoS One       Date:  2018-05-17       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.